Referring to the article: Baiamonte E, Barone R, Contino F, et al. Granulocytecolony stimulating factor plus plerixafor in patients with β-thalassemia major results in the effective mobilization of primitive CD34+ cells with specific gene expression profile, published on Thalassemia Reports 2017; volume 7:6392, the following sentence in the Materials and Mehods section is not correct:
(Filgrastim, Amgen, Thousand Oaks, CA, USA).
Corrected sentence must be intended as follows:
[Myelostim 34 F 33,6 33,6 MUI (263 mcg) (Lenograstim), Italfarmaco S.P.A.]